Clinical trial · Interventional
Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases
Efficacy Evaluation of Strontium-89 Chloride for Differentiated Thyroid Cancer With Bone Metastases
NCT05466812CI-TRIAL-00059752unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Using sensitive markers (such as thyroglobulin, etc) to evaluate the efficacy of strontium-89 chloride (Sr-89) in differentiated thyroid cancer with bone metastases with an aim to breaking out of its palliation effect for bone pain.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Metastases | — | UNRESOLVED | — |
| Thyroid Neoplasm Follicular | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sr-89 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Sr-89 treated group
- description
- Sr-89 treatment
- interventionNames
- Drug: Sr-89
Primary outcomes (6)
- measure
- Change of serum thyroglobulin (Tg) level
- timeFrame
- Through study completion, an average of 1 week in the first months and 1 month thereafter, up to 6 months
- description
- Change of serum Tg level
- measure
- Change of serum thyroglobulin antibody (TgAb) level
- timeFrame
- Through study completion, an average of 1 week in the first months and 1 month thereafter, up to 6 months
- description
- Change of serum TgAb level
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients of differentiated thyroid cancer * Positive uptake by bone metastases on bone scan * Planing to have Sr-89 treatment Exclusion Criteria: * Having received treatment for bone metastases within one month of the study (such as radiotherapy, surgery, targeted therapy, chemotherapy, etc., among which denosumab and bisphosphate were allowed as basic treatment) * Having received radioactive iodine therapy within half a year before the study * There are bone related events, such as fracture, spinal cord compression, etc.
References
Publications (0)
Data not yet available
No reference posted for this study.